Studies show that Johnson & Johnson booster provides strong protection against omicron

(WJW) – Results of two studies indicate Johnson & Johnsons COVID-19 booster shot provides strong protection against the omicron variant.

A study was conducted by the South African Medical Research Council and involved more than 69,000 healthcare professionals from mid-November to mid-December.

According to a statement from Johnson & Johnson, two Johnson & Johnson shots reduced the risk of hospitalization from the variant by up to 85% during the trial.

When a booster shot was given six to nine months after a primary single dose, the vaccine’s effectiveness increased over time from 63% after 0-13 days, to 84% after 14-27 days and 85% one to two months after boost, according to the statement. .

“Data from the (South Africa) study confirm that the Johnson & Johnson COVID-19 booster shot provides 85 percent efficacy against hospitalization in areas where Omicron is dominant. This adds to our growing body of evidence showing that the effectiveness of The Johnson & Johnson COVID-19 vaccine remains strong and stable over time, including against circulating variants such as Omicron and Delta, ”said Mathai Mammen, MD, Ph.D., Global Head, Janssen Research & Development, LLC, Johnson & Johnson, in the release. “We believe the protection may be due to the robust T-cell responses induced by the Johnson & Johnson COVID-19 vaccine. In addition, these data suggest that Omicron does not affect the T cell responses generated by our vaccine. “

In another study, conducted by Beth Israel Deaconess Medical Center, research showed that the use of the Johnson & Johnson shot as a booster for those who received two initial doses of the Pfizer vaccine generated a 41-fold increase in neutralizing antibody responses.

However, using the Pfizer shot as a booster generated a 17-fold increase in neutralizing antibodies, according to the release.

This study involved an analysis of the blood of 65 vaccinated individuals.

“Since the omicron variant is mutated from the original SARS-CoV-2 strain, there is a need to understand how effective currently approved COVID-19 vaccines remain in protecting against serious disease,” said Dan Barouch, MD, Ph.D. .D., Director of the Center for Virology and Vaccine Research at BIDMC, in the publication. “Our analysis shows that a booster shot of the Johnson & Johnson COVID-19 vaccine generated a robust increase in both neutralizing antibodies and T cells against Omicron.”

Follow us on Google News

Disclaimers for

All the information on this website – – is published in good faith and for general information purposes only. does not make any warranties about the completeness, reliability, and accuracy of this information. Any action you take upon the information you find on this website (, is strictly at your own risk. will not be liable for any losses and/or damages in connection with the use of our website.

Give a Comment